Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sushree Mohanty

YOU WONT BELIEVE: Is this under 10 stock the next big biotech winner - You Need To See This

Ardelyx (ARDX) has quietly established itself as one of the most fascinating biotech stories, trading at under $10. With two FDA-approved therapies on the market, IBSRELA and XPHOZAH, delivering consistent growth, Ardelyx is not just another speculative clinical-stage biotech. It is building a sustainable commercial business in specialty medicine.

The company’s second-quarter results showed a kind of momentum rarely seen in small-cap biotech.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.